Crohn's Disease
Conditions
Keywords
Probiotic, capsules, Crohn's disease, recurrent endoscopic ileo-colonic lesions
Brief summary
A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's disease recurrent endoscopic ileo-colonic lesions 12 months after surgery. Patients will consume 900 mg/day of active product (N=56) or control product (N=56) during one year.
Interventions
OTHER1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)
1- 6 test products/day
OTHER2- excipients (150 mg) in capsule (control)
2- 6 control poducts/day
Sponsors
Danone Global Research & Innovation Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male/female at least 18 years old * Diagnosis of Crohn's disease defined by the criteria usually adopted (Gower-Rousseau, 1994) * Crohn's disease mainly limited to the terminal ileum and/or the ascending and transverse colon * Diagnosis of Crohn's disease in agreement with surgical specimen analysis * Patient having given its written consent to take part in the study * Complete resection of all main macroscopic ileo-colonic lesions, as shown by inspection at surgery * To have an ileo-colic resection (right, transverse, left) with an anastomosis that can be inspected by endoscopy * Ability to start oral nutrition and therefore the consumption of the study product within 21 days of surgery * Patient receiving no antibiotics at the beginning of the product consumption
Exclusion criteria
* One or more intestinal resection during the 5 last years before the last surgery * Presence of any severe additional disease * For female patient : pregnancy or breast feeding * For pre-menopausal female patient : no effective contraceptive methods used (combined oestrogen-progestogen pill or Intrauterine Device) * Patient currently in an exclusion period following participation in another clinical trial * Patient in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the patient * Significant presence of Crohn's disease in other intestinal tracts * Small bowel cumulative resection exceeding 1 meter * Patient with ileostomy * Subtotal colectomy with ileo-rectal anastomosis * Severe post-operative septic complications (fistula, peritonitis), leading to administration of more than 15 days of post-operative antibiotherapy) * Intake of unauthorised treatments (mesalazine, olsalazine or sulfasalazine, 5-Aminosalicylates (5-ASA) or 4-Aminosalicylates (4-ASA)) ; corticoïds and immunosuppressors) after surgery except corticoids which will have to be stopped within 6 weeks after surgery according to standardised stepwise dose reductions * Patient under artificial nutrition * Subject with a loss of personal liberty, by administrative or judicial decision, or major with a legal guardian
Countries
France
Outcome results
None listed